Global Chronic Disease Management Therapeutics and Device Technologies Market Size study & Forecast, by Disease (Cardiovascular diseases (CVD), Diabetes, Cancer, Chronic respiratory diseases, Chronic kidney diseases, Neurological disorders, Others (such a

Global Chronic Disease Management Therapeutics and Device Technologies Market Size study & Forecast, by Disease (Cardiovascular diseases (CVD), Diabetes, Cancer, Chronic respiratory diseases, Chronic kidney diseases, Neurological disorders, Others (such as autoimmune diseases, gastrointestinal disorders, and many)) by Therapy (Medications, Rehabilitation therapy, Behavioral therapy, Others (such as gene therapy, stem cell therapy, and many)), by Device (Blood glucose monitoring devices, Blood pressure monitors, Cardiac monitors, Respiratory therapy devices, Kidney dialysis machines, Neurostimulation devices, Others (such as insulin pumps, continuous glucose monitoring devices, and many)) and Regional Analysis, 2023-2030

Global Chronic Disease Management Therapeutics and Device Technologies Market is valued at approximately USD 20.35 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 1.5% over the forecast period 2023-2030. The global chronic disease management therapeutics and device technologies market can be defined as the market for products and services that are used in the treatment and management of chronic diseases, such as diabetes, cardiovascular disease, cancer, respiratory disease, and others. This includes pharmaceuticals, medical devices, and other healthcare technologies that are designed to improve patient outcomes and quality of life by managing the symptoms and complications associated with chronic diseases. The driving factors for the Global Chronic Disease Management Therapeutics and Device Technologies Market are the growing prevalence of chronic diseases, growing geriatric population and rising healthcare expenditure. Moreover, increasing demand for innovative therapies and advances in medical technology is creating lucrative growth opportunities for the market over the forecast period 2023-2030.

The Global Burden of Disease study estimated that in 2020, 1.7 billion people worldwide had at least one chronic disease, and 415 million had multiple chronic diseases. The global burden of chronic diseases is increasing, with conditions such as diabetes, cardiovascular disease, cancer, and respiratory disease affecting a growing number of people worldwide. This is driving demand for new and effective treatments and management strategies. For instance, in 2021, the International Diabetes Federation (IDF) reported that the global prevalence of diabetes had risen to 10.5% among adults, up from 9.3% in 2019. This represents an estimated 463 million adults living with diabetes worldwide. Similarly, according to the American Cancer Society, the global cancer burden is expected to rise to 29.5 million new cases annually by 2040, up from an estimated 19.3 million new cases in 2020. This represents an increase of more than 50% in just 20 years. However, the high cost of Chronic Disease Management Therapeutics and Device Technologies stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Chronic Disease Management Therapeutics and Device Technologies Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is the dominating market for chronic disease management therapeutics and device technologies, accounting for a significant share of the global market. The region's strong healthcare infrastructure, high healthcare spending, and favorable reimbursement policies are driving the market growth. The Asia Pacific region is the fastest growing region in the chronic disease management therapeutics and device technologies market in the coming years. Factors driving market growth include the growing population, rising healthcare spending, and increasing prevalence of chronic diseases.

Major market player included in this report are:
Medtronic plc
Novo Nordisk A/S
Abbott Laboratories
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson & Johnson Consumer Inc.
Sanofi S.A.
Dexcom, Inc.
AstraZeneca plc
Becton, Dickinson and Company (BD)

Recent Developments in the Market:
 In September 2020, Medtronic launched its MiniMed 770G insulin pump system, which uses advanced algorithms to automatically adjust insulin delivery to help people with diabetes better manage their blood sugar levels.
 In June 2020, Abbott received FDA clearance for its FreeStyle Libre 2 continuous glucose monitoring system, which allows people with diabetes to monitor their glucose levels without the need for fingerstick.
Global Chronic Disease Management Therapeutics and Device Technologies Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Disease, Therapy, Device, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Disease offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Disease:
Cardiovascular diseases (CVD)
Diabetes
Cancer
Chronic respiratory diseases
Chronic kidney diseases
Neurological disorders
Others (such as autoimmune diseases, gastrointestinal disorders, and many)
By Therapy:
Medications
Rehabilitation therapy
Behavioral therapy
Others (such as gene therapy, stem cell therapy, and many)
By Device:
Blood glucose monitoring devices
Blood pressure monitors
Cardiac monitors
Respiratory therapy devices
Kidney dialysis machines
Neurostimulation devices
Others (such as insulin pumps, continuous glucose monitoring devices, and many)

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned

Medtronic plc
Novo Nordisk A/S
Abbott Laboratories
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson & Johnson Consumer Inc.
Sanofi S.A.
Dexcom, Inc.
AstraZeneca plc
Becton, Dickinson and Company (BD)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.